Results 21 to 30 of about 25,190 (292)

Development and Validation of a Liquid Chromatography High-Resolution Mass Spectrometry Method for Blood Desmopressin Quantification and Its Application in Hemophilia A Patients. [PDF]

Rapid Commun Mass Spectrom
ABSTRACT Desmopressin (DDAVP), which indirectly increases Coagulation Factor VIII concentrations in the blood, is a common treatment for bleeding disorders such as von Willebrand disease or hemophilia A. However, DDAVP exhibits significant variability in response due to interindividual differences in pharmacokinetics.
Hodin S, Escal J, Feliu C, Pontis A, Josset L, Serban A, Guillet B, Delavenne X.   +7 more
europepmc   +2 more sources

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD

Blood Advances, 2019
: The bleeding phenotype of patients with type 1 von Willebrand disease (VWD) is very heterogeneous. We hypothesized that this heterogeneity may partly be explained by variability in response of von Willebrand factor (VWF) and factor VIII (FVIII) levels ...
Ferdows Atiq, Lisette M. Schütte, Agnes E.M. Looijen, Johan Boender, Marjon H. Cnossen, Jeroen Eikenboom, Moniek P.M. de Maat, Marieke J. H.A. Kruip, Frank W.G. Leebeek   +8 more
doaj   +2 more sources

Desmopressin as a hemostatic and blood sparing agent in bleeding disorders

European Journal of Haematology, 2023
Intranasal, subcutaneous, or intravenous desmopressin can be utilized to release von Willebrand Factor and Factor VIII into circulation, enhance platelet adhesion and shorten bleeding time.
Ajay Mohinani, Sarah Patel, Virginia Tan, Thomas Kartika, S. Olson, T. Deloughery, J. Shatzel   +6 more
semanticscholar   +1 more source

Acquired von Willebrand Syndrome and Desmopressin Resistance During Venovenous Extracorporeal Membrane Oxygenation in Patients With COVID-19: A Prospective Observational Study

Critical Care Medicine, 2022
OBJECTIVES: Although COVID-19 is associated with high von Willebrand factor (vWF) parameters promoting thrombosis, venovenous extracorporeal membrane oxygenation (vvECMO) is associated with the development of acquired von Willebrand syndrome (AVWS ...
J. Kalbhenn, H. Glonnegger, M. Büchsel, H. Priebe, B. Zieger   +4 more
semanticscholar   +1 more source

Mucoadhesive Electrospun Nanofiber-Based Hybrid System with Controlled and Unidirectional Release of Desmopressin

International Journal of Molecular Sciences, 2022
The sublingual mucosa is an attractive route for drug delivery, although challenged by a continuous flow of saliva that leads to a loss of drug by swallowing.
Mai Bay Stie, J. Gätke, I. Chronakis, J. Jacobsen, H. M. Nielsen   +4 more
semanticscholar   +1 more source

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease

Blood Advances, 2022
Key Points All type 1 VWD patients without a VWF gene variant have a complete response to desmopressin. In type 1 and type 2 VWD patients with a VWF gene variant, desmopressin response highly depends on the causative VWF gene variant.
F. Atiq, J. Heijdra, Fleur Snijders, J. Boender, E. Kempers, W. V. van Heerde, D. Maas, Sandy Krouwel, S. Schoormans, J. de Meris, S. Schols, K. V. van Galen, J. G. van der Bom, M. Cnossen, K. Meijer, K. Fijnvandraat, J. Eikenboom, F. Leebeek   +17 more
semanticscholar   +1 more source

IS DESMOPRESSIN USEFUL IN THE EVALUATION OF CUSHING'S SYNDROME?

Journal of Clinical Endocrinology and Metabolism, 2022
The desmopressin test was first described 30 years ago. Based on the differential secretagogue properties of desmopressin on ACTH release between normal and corticotroph tumor cells, this test was intended to facilitate the diagnosis of Cushing's ...
F. Castinetti, A. Lacroix
semanticscholar   +1 more source

Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial

Investigative and Clinical Urology, 2021
Purpose To assess the efficacy of desmopressin plus anticholinergic combination therapy as first-line treatment for children with primary monosymptomatic nocturnal enuresis (PMNE) and to analyze this combination's effect on functional bladder capacity ...
M. Shim, W. Bang, C. Oh, M. Kang, J. Cho
semanticscholar   +1 more source

Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach

Medical archives, 2021
Background: One of the common pediatric issues is monosymptomatic nocturnal enuresis (MNE). MNE is involuntarily urine-voiding in night sleep without lower urinary tract symptoms, such as daytime frequency, incontinence, or urgency.
A. Purnomo, B. Daryanto, Pradana Nurhadi
semanticscholar   +1 more source

Effects of desmopressin acetate administration in healthy dogs receiving prednisolone

Journal of Veterinary Internal Medicine, 2021
Background Glucocorticoids are used for a variety of purposes in veterinary medicine but often are associated with clinically important adverse effects. Polyuria and polydipsia are the most frustrating adverse effects noted by owners.
Pamela Galati, Todd Archer, Robyn Jolly, Alyssa Sullivant, Robert Wills, Patty Lathan   +5 more
doaj   +1 more source